Picture of Bruker logo

BRKR — Bruker News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Bruker Q3 revenue tops estimates on US academic unit strength

Bruker Q3 revenue tops estimates on US academic unit strength


Overview

  • Scientific instruments maker's Q3 revenue rose 1.6%, slightly beating analyst expectations

  • Adjusted EPS for Q3 rose 24%, beating analyst expectations

  • Company reconfirmed full-year 2026 organic revenue growth and non-GAAP EPS guidance


Outlook

  • Bruker sees FY26 revenue of $3.52 bln to $3.56 bln, up 2.5%-3.5% yoy

  • Company expects FY26 non-GAAP EPS of $2.10 to $2.15, up 15%-17% yoy

  • Company expects revenue growth acceleration and double-digit EPS growth in FY27


Result Drivers

  • COST DISCIPLINE - Co said margin expansion and EPS growth were driven by cost discipline and execution

  • BOOKING TRENDS - Co reported continued positive booking trends and strengthening demand in most end markets, including US academic market

  • BEST SEGMENT GROWTH - Revenue growth in the BEST segment outpaced other segments, with 11.2% increase yoy


Company press release: ID:nBw3LwkgHa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$874 mln

$868.83 mln (12 Analysts)

Q3 Adjusted EPS

Beat

$0.56

$0.42 (12 Analysts)

Q3 Net Loss

$109.70 mln

Q3 Adjusted Operating Margin

16.30%

Q3 Gross Profit

$429.30 mln

Q3 Operating Expenses

$520.30 mln

Q3 Operating Income

-$91 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Bruker Corporation is $62.00, about 9.7% above its November 3 closing price of $56.50

  • The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 27 three months ago


Reuters Recommended Reads

  • Nov 3 - Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

  • Nov 3 - AMETEK Q3 sales beat estimates, raises outlook

  • Nov 3 - Zebra Technologies Q3 revenue beats on strong demand across segments


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Bruker

See all news